(NASDAQ: IRWD) Ironwood Pharmaceuticals's forecast annual revenue growth rate of -3.62% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 6.21%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.85%.
Ironwood Pharmaceuticals's revenue in 2025 is $378,418,000.On average, 2 Wall Street analysts forecast IRWD's revenue for 2025 to be $43,031,633,533, with the lowest IRWD revenue forecast at $42,247,494,432, and the highest IRWD revenue forecast at $43,815,772,634. On average, 4 Wall Street analysts forecast IRWD's revenue for 2026 to be $48,307,289,400, with the lowest IRWD revenue forecast at $41,143,298,555, and the highest IRWD revenue forecast at $61,274,869,765.
In 2027, IRWD is forecast to generate $54,417,653,339 in revenue, with the lowest revenue forecast at $45,288,033,804 and the highest revenue forecast at $63,547,272,875.